KF
RVNC

Krilogy Financial’s Revance Therapeutics, Inc. RVNC Stock Holding History

Krilogy Financial’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-100
Closed -$3K – 614
2015
Q3 		$3K Buy
+100
New +$3.04K ﹤0.01% 526

Other funds holding RVNC

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NHG
NQ HCIF GP Raleigh, North Carolina $50.2M AUM 45.53% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Krilogy Financial's RVNC Position: Q4 2015 in Review

Krilogy Financial sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2015, closing a stake of 100 shares — an estimated $3K sold.

Krilogy Financial first reported a position in RVNC in Q3 2015 and held it in 1 quarter. The position peaked at $3K in Q3 2015. 104 funds tracked by Wall St. Rank hold RVNC as of Q4 2015.

  • Krilogy Financial reported no remaining Revance Therapeutics, Inc. position as of Q4 2015 after selling out during the quarter.
  • Krilogy Financial sold 100 Revance Therapeutics, Inc. shares in Q4 2015, an estimated $3K.
  • Krilogy Financial first reported a position in Revance Therapeutics, Inc. in Q3 2015 and held it in 1 quarter.
  • Krilogy Financial's Revance Therapeutics, Inc. position peaked at $3K in Q3 2015.
  • 104 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2015.

Based on Krilogy Financial's 13F filing for Q4 2015, filed 29 Feb 2016.